Crossmark

Xenon treatment after severe traumatic brain injury improves locomotor outcome, reduces acute neuronal loss and enhances early beneficial neuroinflammation: a randomized, blinded, controlled animal study

Crossref DOI link: https://doi.org/10.1186/s13054-020-03373-9

Published Online: 2020-11-27

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Campos-Pires, Rita

Onggradito, Haldis

Ujvari, Eszter

Karimi, Shughoofa

Valeo, Flavia

Aldhoun, Jitka

Edge, Christopher J.

Franks, Nicholas P.

Dickinson, Robert https://orcid.org/0000-0003-2423-2108
Funding

Funding for this research was provided by:

Medical Research Council (MR/N027736/1)

Association of Paediatric Anaesthetists of Great Britain and Ireland (WKR0-2019-0033, WKR0-2019-0033)

Gas Safety Trust

Royal Centre for Defence Medicine
License Information

Text and Data Mining valid from 2020-11-27

Version of Record valid from 2020-11-27
More Information

Article History

Received: 13 August 2020

Accepted: 4 November 2020

First Online: 27 November 2020

Ethics approval and consent to participate

: All experiments complied with the UK Animals Scientific Procedures Act (1986) and were approved by the Animal Welfare and Ethical Review Body of Imperial College London. We designed our study to comply with the ARRIVE guidelines.

: Not applicable.

: Nicholas Franks has disclosed being a named inventor on a number of patents relating to the use of xenon as a neuroprotectant and has a financial interest in the use of xenon as a neuroprotectant. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Document is current

Any future updates will be listed below